Sankala Group’s Cytokinetics CYTK Stock Holding History

Sankala Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.8K	Hold	201	–	–	0.01%	348
2025 Q4	$12.5K	Buy	+201	New	+$12.5K	0.01%	362

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sankala Group's CYTK Position: Q1 2026 in Review

Sankala Group held its Cytokinetics (CYTK) position steady in Q1 2026 at 201 shares worth $12.8K. The position accounts for 0.01% of the portfolio, ranked #348.

Sankala Group first reported a position in CYTK in Q4 2025 and has held it in 2 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Sankala Group held 201 shares of Cytokinetics worth $12.8K as of Q1 2026.
Sankala Group left its Cytokinetics share count unchanged in Q1 2026.
Cytokinetics made up 0.01% of Sankala Group's portfolio in Q1 2026, its #348 holding.
Sankala Group first reported a position in Cytokinetics in Q4 2025 and has held it in 2 quarters since.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.